fashion -WSS

fashion

author：hotspot 2025-10-02 22:26:55 - browse：76665

FDA stop sign — Sarah Silbiger/Getty Images

The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products.

The regulator this week posted warning letters that it sent to two websites, Synthetix Inc. DBA Helix Chemical Supply and US Chem Labs. Though those websites say their chemicals are “for research use” and “not for human consumption,” the FDA said it found evidence on their pages showing that their products are indeed intended for human use, such as information about dosing and claims about the clinical benefits of the products.

The two websites did not immediately respond to requests for comment. The FDA said they have 15 working days to respond and detail the steps they’ve taken to address any violations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： NIH nominee Bertagnolli will get October confirmation hearing

Wikipedia

WSS

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Wegovy’s successful heart trial raises vital question about weight loss

Emergent cuts jobs, executive role in business shake

What drug price negotiations mean for Medicare Part D

NIH nominee Bertagnolli will get October confirmation hearing

Why Novartis is changing the name of its research labs

entertainment

fashion

focus

As demand for Covid shots wanes, Moderna seeks its next success

'Make People Better': The CRISPR babies story you probably don't know

Anesthesiologist group: stop taking Ozempic before surgery

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

BioMarin wins approval for gene therapy to treat hemophilia A

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

As demand for Covid shots wanes, Moderna seeks its next success

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

BioMarin wins approval for gene therapy to treat hemophilia A

ALS advocates say criticism of new drugs misses bigger picture

hotspot

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Anavex keeps shifting the goalposts in its clinical trials

What American doctors can learn from their Israeli counterparts

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

focus

Wikipedia

Wikipedia

knowledge